[Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis]

C Martín; X M Lens; A Prieto; R Alonso; B Correa; V Arcocha; A Soto

[Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis]

An Otorrinolaringol Ibero Am. 1994;21(2):193-8.

[Article in Spanish]

Authors

C Martín¹, X M Lens, A Prieto, R Alonso, B Correa, V Arcocha, A Soto

Affiliation

¹ Hospital General De Galicia, Facultad de Medicina, Universidad de Santiago, Santiago de Compostela.

PMID: 8209972

Abstract

The AA. have studied the Desferrioxamine ototoxicity with high frequency audiometry (HFA), given the drug as a test for diagnosis of aluminium-related done disease in patients under dialysis. The dose of 10 mg/kg presents high sensitivity and low ototoxicity.

Publication types

English Abstract

MeSH terms

Adult
Aluminum / analysis
Aluminum / blood*
Aluminum / metabolism
Audiometry
Bone Diseases / metabolism
Bone Diseases / therapy*
Deferoxamine / adverse effects*
Deferoxamine / pharmacology
Deferoxamine / therapeutic use
Dose-Response Relationship, Drug
Female
Hearing Disorders / diagnosis
Hearing Disorders / etiology*
Humans
Infant, Newborn
Male
Middle Aged
Renal Dialysis*

Substances

Aluminum
Deferoxamine